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Breast cancer is a major health care problem that aﬀects more than one million women yearly. While it is traditionally thought
of as a disease of the industrialized world, around 45% of breast cancer cases and 55% of breast cancer deaths occur in low and
middle income countries. Managing breast cancer in low income countries poses a diﬀerent set of challenges including access
to screening, stage at presentation, adequacy of management and availability of therapeutic interventions. In this paper, we will
review the challenges faced in the managementof breast cancer in low and middle income countries.
1.Introduction
Breast cancer is the most common cancer of women, and its
incidence is rising especially in developing countries. Global
burden of breast cancer in women, measured by incidence,
mortality, and economic costs, is substantial and on the
increase. Worldwide, it is estimated that more than one
million women are diagnosed with breast cancer every year,
and more than 400,000 will die from the disease.
In low- and middle-income countries (LMCs), the
infrastructure andresources forroutine screening mammog-
raphy are often unavailable. In such countries, breast cancer
is usually diagnosed at late stages, and, due to inadequate
resources, women with breast cancer may receive inadequate
treatment or palliative care.
Many barriers are identiﬁed for breast cancer patients
in LMCs which may correlate with the lower incidence
and higher mortality in those countries compared to
high-income countries. These barriers include the lack of
breast cancer awareness due to poor health awareness and
education, lack of screening programs due to the lack of
governmental support and inadequate funds, social barriers
to early diagnosis and treatment due to low priority for
women health issues in predominantly patriarchal devel-
oping societies, fear of loss of employment and the social
taboo of cancersand misconceptionsabout cancertreatment
and outcomes, lack of standardized treatment protocols
with diversity of clinical practice, health care standards and
infrastructure, and ﬁnally poor followup data and the lack of
mortality data.
2.Epidemiology
Breast cancer is the most common cancer in women,
accounting for 23% of all female cancers around the globe
[1]. There is a marked geographical variation in incidence
rates, being highest in the developed world and lowest in
the developing countries of the third world. However, in
recent years, the incidence of breast cancer has shown an
alarming increasing trend [2]. It is estimated that 45% of
the 1.35 million new cases diagnosed each year, and more
than 55% of breast cancer related deaths, occur in low-
a n dm i d d l ei n c o m ec o u n t r i e s[ 3]. An estimated 1.7 million
women will be diagnosed with breast cancer in 2020—a 26%
increase from current levels, mostly in the developing world
[4].
The most widely cited reason for the global increase in
breast cancer is the “westernization” of the developing world
[2]. Social factors like smoking, alcohol, and obesity are2 Journal of Oncology
becoming more common in the developing countries and
areincreasingly accepted[5].Hormonalriskfactorslikeearly
menarche,delayedparity,andreducedbreastfeedingarenow
being observed in low- and middle-income countries [2].
Potential explanations for this are the wider adoption of the
western diet and lower exercise levels.
Breast cancer incidence has, historically, been less com-
mon in Asia compared to the West. However, recent
statistical data reveal breast cancer to be the leading cause
of cancer in Southeast Asian women and second only to
gastric cancer in East Asian women and to cervical cancer
in women in South-Central Asia. Countries with the most
developed registries have documented increases: rates in
Japan, Singapore, and Korea have doubled or tripled in the
past 40 years, and China’s urban registries document 20 to
30% increases in the past decade [2]. In China’s commercial
center of Shanghai, 55 out of every 100000 women have
breast cancer, a 31% increase since 1997.
While breast cancer incidence progressively increases
with age in the western countries, a diﬀerent pattern is being
observed in Japanese women. The breast cancer incidence
rate seems to plateau after the age of 50 in Japanese women
[6].
In India, almost 100000 women are diagnosed with
breast cancer every year, with increases concentrated in
urban areas, and a rise to 131 000 cases is predicted by 2020
[4]. The incidenceofbreast cancerhas beenrising by0.5% to
2% per year across all regions of India, and in all age groups,
but has been even higher in women younger than 45 years
of age. Almost half of the Indian breast cancer patients are
premenopausal, with the average age reported as 50 to 53
years in various studies [4].
In Mexico, cervical cancer remains a signiﬁcant health
care problem in many areas of the country. Breast cancer, on
theotherhand, isbeingdetectedathigherrates,and, insome
parts of the country, it has surpassed cervical cancer as the
number one cancer in women. The most recent registry data
report around 12,500 breast cancer cases with around 4000
deaths from the disease. Although breast cancer seems to be
diagnosedatayoungeragethaninmore developedcountries
(more than a decade younger at diagnosis), this seems to be
partially related to the number of younger people in Mexico
[7].
In Africa, the trends are diﬃcult to evaluate; however,
local registries report a doubling of rates over the past 40
years, but the degree to which these ﬁgures represent real
increases, as opposed to changes in disease tracking and
reporting, is unclear.
In the Arab world, a scarcity of data is remarkable;
some countries either have a national or regional registry,
while others have no data. However, breast cancer is the
most common cancer in Arabic women and aﬀects younger
women than their counterparts in industrialized nations.
In Lebanon, the age-standardized incidence rates were
46.7/100000 in 1998, 69/100000 in 2004, and 84/100000
in 2007. Although these ﬁgures remain lower than that
observed in developed countries, they are substantially
higher than in other developing countries of the region or
thenon-Jews in Israel. This isprobablyattributedtothewide
adoption of screening programs and to a better awareness of
breast cancer and its early signs. Clinical observation from
otherArabcountriesandcomparativeage-standardized rates
and age-speciﬁc standardized incidences show that breast
cancer is seen in younger groups. The ASR for breast cancer
in women younger than 50y in Lebanon is 153/100000
in 1998, 194/100000 in 2004, and 286/100000 in 2007,
compared to 42.5/100,000 for breast cancer cases in the
United States. The median age of breast cancer in Lebanon
is 52 years, with 49.1% of cases younger than 50, compared
to 63 years for developed countries such as the US with 50%
of cases over 65 years of age [1, 8, 9].
The Middle East Cancer Consortium (MECC) presents
information about cancer incidence for populations in
Cyprus, Egypt (Gharbia Region), Israel (Jews and Arabs),
and Jordan for the period 1996–2001. The MECC ﬁndings
are compared with those from the US Surveillance,Epidemi-
ology, and End Results (SEER) Program: age-standardized
incidence rates (ASRs) per 100,000 females were highest
among Israeli Jews (93.1), similar to the rates reported in the
USSEERfemales(97.2).These rateswere signiﬁcantlyhigher
than those reported in Cypriot (57.7), Egyptian (49.6),
Jordanian (38.0), and Israeli Arab (36.7) females. The high
incidence rates described in Israeli Jews were similar to those
described in North American and West European countries,
while the lower rates in the other Middle Eastern groups
were more similar to rates in Mediterranean Europe, Eastern
Europe, and some of Asia and Africa [10].
Comparisons with SEER data reveal that Pakistan has
a younger patient population with larger tumors, higher
grades, and more advanced disease stage on presentation
than does the United States. Receptor-negative tumors are
also more common [11].
3.Screening andEarlyDetection
Proper screening necessitates the presence of certain ele-
ments which include high-quality screening using mam-
mography, high coverage and participation and eﬀective
referral systems for diagnosis and treatment [12]. It is costly
to implement such screening strategies thereby rendering
screening unfeasible in low- and middle-income countries
(LMCs). It is necessary that screening be implemented
in LMCs in order to facilitate early detection and avoid
advanced stage cancers at presentation. However, with mam-
mography being the gold standard of screening in developed
countries, it is arguable whether to put it into use in
LMCs. Major obstacles involve high cost, lack of health care
infrastructure, encouragingwomentogetscreened, andhigh
incidence of breast cancer occurring in younger populations
of women aged 40–49 in which no signiﬁcant beneﬁt of
mammography was seen in this age group [4, 13, 14]. For
these reasons of impracticality, the Breast Health Global
Initiative (BHGI) was founded in order to develop feasible,
cost-eﬀective, and culturally speciﬁc guidelines for LMCs.
The guidelines were constituted of four levels of resources
which include basic, limited, enhanced, and maximal. The
basic-level resources were constituted of basic breast healthJournal of Oncology 3
awareness through education and self-examination and a
clinical breast exam (CBE). The limited level includes
CBE in addition to diagnostic ultrasound with or without
mammography within limited ﬁnancial means and modest
health care systems. The third level involves mammography
screening and the maximal level includes population-based
mammographic screening [15]. Using this stepwise-based
approach, advancement in LMCs health care systems may be
achieved.
There is emerging evidence that awareness campaigns
in LMCs can improve adherence to screening guidelines. In
Lebanon, fournational surveyswere conductedin collabora-
tion with the National Breast Cancer Awareness Campaigns.
These surveys revealed a slight improvement in utilization
of mammography from 11% to 18% within a period of 12
months [16]. These results reveal an increased tendency to
use mammography, however, at a low pace. Guidelines for
screening of breast cancer have been established in Lebanon.
These include a mammography scan every year starting at
the age of 40, women with family history of breast cancer
should start screening 10 years prior to the onset of the ﬁrst
case in the family, all women are to have an annual CBE
with mammography and one CBE every three years between
the age of 20 and 40, all women are to perform breast self-
examination (BSE) once per month starting at the age of
20, two routine views are needed for a valid mammography
which include craniocaudal and lateral oblique, and ﬁnally
ultrasound is not recommended for asymptomatic women
[17].
4.ClinicalPresentationand Pathology
Although <5% of breast cancer diagnosed in mammograph-
ically screened population are stage III tumors [18], the
reality is diﬀerent from that in LMCs. With inadequate
resources for early detection of breast cancer, the majority
of patients from LMCs presents with advanced or metastatic
disease. In a recent study done in Pakistan, the clinical
presentation of patients was highest in advanced stages III
and IV amounting to 65.7% in poor societies and 43.6% in
middle- and high-income societies [11]. Both of these values
are signiﬁcantly higher than the 18.9% and 11.3% incidence
of stage III and IV among African-Americans and American
Whites, respectively, [18]. In another study in Nigeria, 72%
of patients presented with stage III or IV disease [5]. In Arab
countries, the data also show similar trends with a rate of
advanced or metastatic stage reaching 60 to 80% of cases
[1]. In Egypt, stages III and IV constitute 68% of all breast
cancer cases [1, 19, 20]. As for Saudi Arabia, stages III and
IV constitute about 46% of cases [21]. Also in Oman the
rates are high amounting to 50.8% [22]. Eﬀorts aimed at
earlydetectioncandecreasestageatdiagnosisandpotentially
improve the probability of survival and cure.
Histologic diagnosis is necessary before initiating treat-
ment. Choosing the type of biopsy whether ﬁne nee-
dle aspiration cytology, core needle biopsy, or excisional
biopsy depends on the resources available. Again the BHGI
has deﬁned the basic level of diagnosis and pathology
to include history, CBE, physical exam, and interpreting
specimens from surgical biopsy and ﬁne needle aspiration
to include tumor size, lymph node status, histologic type,
and tumor grade. The limited level includes mammographic
or ultrasound imaging of the breast. Core needle biopsy
and image-guided sampling are used in order to determine
estrogen receptor and progesterone receptor status as well
as margin status. Also, within this level, resources should
be allocated to include evaluation for metastasis with chest
X-rays, ultrasound of liver, as well as blood studies. As for
the enhanced level of diagnosis, it includes preoperative
needle localization under mammographic or ultrasound
guidance, and improved services involve the presence of
a cytopathologist. Higher-level resources within this level
could include bone scanning for metastatic examination.
Finally, the maximal level could involve stereotactic biopsy,
HER-2/neustatus, sentinel node biopsy, immunohistochem-
istry staining of sentinel nodes for cytokeratin to detect
micrometastases, and several imaging studies that include
the use of CT scanning, PET scanning, MIBI scanning, as
well as breast MRI [15, 23].
5.AdequacyofManagement
Mastectomy rates in Arab countries are high amounting to
79.9%–82% in Egypt, 65% in Oman, 70% among Pales-
tinians, 88% in Syria, and 82.4% in Tunisia [1, 20, 22, 24–
26]. In other LMCs, the picture is very similar. In India, the
majority of patients present with stage IIIa and IIIb tumors
reaching levels of 62%. Modiﬁed radical mastectomy after or
without neoadjuvant chemotherapy is the most commonly
used procedure for almost all types of breast cancers [27].
A major reason behind this practice could be related to
the advanced stage that patients present with and the low
numberofradiationcenterssinceradiationtherapyisimpor-
tant in the treatment of breast cancer after breast conserving
surgery [5, 28]. This necessitates the presence of suﬃcient
radiation facilities and establishing early detection methods
in order to provide proper treatment upon detection with
higher survival rates of less-advanced disease stages.
The younger age at presentation in LMCs has been
associated with a worse outcome compared to patients
presenting at an older age. In a study from Lebanon,
women younger than 35 years at presentation had a worse
survival despite receiving more chemotherapy and adequate
hormonal therapy compared to women presenting with the
disease between 35 and 50 years and women older than 50
years old [28].
6.TreatmentGuidelines
The BHGI has also deﬁned treatment guidelines for each
stage at presentation according to the resource levelavailable.
In stage I breast cancer, the primary treatment modality
at the basic level constitutes modiﬁed radical mastectomy
due to the unavailability of radiation therapy. Systemic
therapy at this level includes the incorporation of tamox-
ifen in both premenopausal and postmenopausal women.
At the limited level, breast-conserving surgery as well as4 Journal of Oncology
sentinel lymph node biopsy with blue dye becomes feasible,
together with the incorporation of adjuvant anthracycline-
based chemotherapy such as adriamycin, cyclophosphamide,
or classical CMF (cyclophosphamide, methotrexate, and
5-FU). Moving to the enhanced level of resources, sentinel
lymph node biopsy using radiotracer, breast-reconstruction
surgery, aswell as breast-conserving whole-breast irradiation
as part of breast conserving surgery become applicable.
Adjuvant chemotherapy may include the use of taxanes,
while adjuvant endocrinal therapy may include the use
of aromatase inhibitors and luteinizing hormone-releasing
hormone (LHRH) agonists. Within this level as well, use
of trastuzumab for HER2-neu-positive disease becomes
feasible. At the maximal level, dose-dense chemotherapy
can be implemented. In stage II, the basic level includes
the use of cytotoxic chemotherapy in addition to modiﬁed
radical mastectomy and systemic hormonal therapy that
are the basic treatment strategies for stage I breast cancer
at this level. Another diﬀerence between stage I and II
breast cancer includes the incorporation of postmastectomy
irradiation of chest wall and regional nodes for high-risk
cases at the limited level [29]. Locally advanced breast cancer
(LABC) represents a wide variety of clinical presentations
including large tumors (>5cm), extensive regional lymph
node involvement, direct involvement of the underlying
chest wall or skin with edema or satellite skin nodules
together with inﬂammatory breast cancer. In the TNM
staging classiﬁcation of LABC is represented by stages IIIA,
IIIB,andIIIC[30].Incountriesoflimitedresources,LABCis
consideredto be the commonest formof presentationaswell
[31, 32]. Combined modality therapy utilizing neoadjuvant
chemotherapy followed by locoregional therapy (surgery,
radiation, or both) is emerging globally as the standard
of care for LABC including inﬂammatory breast cancer.
At the basic level of resources, patients are treated with
neoadjuvant or adjuvant anthracycline-based chemotherapy
and modiﬁed radical mastectomy. Preoperative or postop-
erative hormonal therapy may be given to patients with
medical comorbidities who are unable to tolerate systemic
chemotherapy. Postmastectomy irradiation of chest wall and
regional lymph nodes becomes incorporated at the limited
level of resources. Eﬀorts should be made to incorporate
it at the basic level as well. Breast-conserving surgery,
breast-reconstruction surgery, and breast-conserving whole
breast irradiation as part of breast conserving therapy are
feasible by shifting to the enhanced and maximal levels.
With neoadjuvant chemotherapy, a large number of patients
are undergoing conservative surgery with axillary dissection
and radiation [29] .H o w e v e r ,f o rp a t i e n t st ou n d e r g ob r e a s t
conservation, they require to meet certain criteria because
patients with locally advanced disease are more likely to have
locoregional recurrence. Criteria for patients undergoing
conservative therapy after chemotherapy include a solitary
primary tumor ≤4cm in size or two primary tumors within
as p h e r e<4cm, absence of multiple breast calciﬁcations, no
skin involvement, the ratio of tumor to breast size is small
enough for good cosmetic result, clinically node negative,
absence of extensive involvement of breast or dermis, and
no contraindications for radiotherapy [33]. Inclusion of
taxanes, aromatase inhibitors, as well as trastuzumab (for
HER2-positive disease) becomes implemented at these levels
as well.
Patients with metastatic breast cancer are unlikely to
be cured of their disease by any means. Available thera-
peutic modalities are local (radiation therapy or surgery)
or systemic therapy (endocrine therapy, chemotherapy, or
molecularly targeted therapies), most of which are not
present in countries with limited resources. Thus, at the
basic level, locoregional treatment available is total mastec-
tomy for ipsilateral breast tumor recurrence and the use
of tamoxifen as systemic therapy. These resources extend
to include palliative radiation therapy and anthracycline-
based chemotherapy or CMF at the limited level. Sequential
combination chemotherapy, use of trastuzumab, lapatinib,
and bisphosphonates become available at the enhanced level.
These resources in addition to bevacizumab and fulvestrant
become incorporated into the management strategy at the
maximal level of resources [29].
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